Until recently, genomics was a «read-only» science. But scientists led by Rory Johnson at the University of Bern and the Centre for Genomic Regulation in Barcelona, have now developed a tool for quick and easy deletion of DNA in living cells.
This software will boost efforts to understand the vast regions of non-coding DNA, or «Dark Matter», in our DNA and may lead to discovery of new disease-causing genes and potential new drugs.
Genomics is the field of research studying how our «genome», or entire DNA sequence, specifies a human being, and how errors in this sequence give rise to diseases. Genomics was recently a «read-only» endeavour: researchers used powerful technology to read genomes’ sequence and their regulatory layers. However until recently, there was no way to edit or delete DNA for either basic research objectives, or for potential therapeutic interventions.
Just a few years ago, this outlook changed dramatically with the discovery of a revolutionary technique for editing genomes: «CRISPR-Cas9». CRISPR-Cas9 is a molecular tool composed of two simple components: a molecular barcode, called «sgRNA», which is designed by the researcher to recognise one precise location in the genome; and a protein, Cas9, that binds to a structured loop in the sgRNA. By introducing these two units, researchers may perform a wide range of operations on specific pieces of genomic DNA, from introducing small mutations, to regulating gene activity, to tagging it with small sequences. Until recently most studies employing CRISPR-Cas9 were aimed at silencing protein-coding genes, the best-studied part of our genome.
However our genome consists of 99% of DNA that does not encode any protein. Often described as the «Dark Matter» of the genome, this «non-coding DNA» is recognised to be crucially important for understanding all aspects of human biology, including disease and evolution. Until recently, the experimental tools to study this have not been available.
Researchers studying non-coding DNA have been particularly excited about the discovery of CRISPR-Cas9 because it can be used as a powerful tool for studying non-coding DNA for the first time. Prof Rory Johnson, at the Centre for Genomic Regulation (CRG) in Barcelona, Spain and now at the National Center of Competence in Research (NCCR) RNA & Disease and Department of Clinical Research of the University of Bern, recently created a tool based on CRISPR-Cas9, called «DECKO», which can be used to delete any desired piece of non-coding DNA. The unique advantage of DECKO is that it uses two individual sgRNAs, acting like two molecular scissors that snip out a piece of DNA. Numerous researchers worldwide have adopted this approach, attracted by its simplicity and effectiveness.
While working on DECKO, Johnson and colleagues realised that no software was available for designing the pairs of sgRNAs that are required, meaning that designing deletion experiments was time-consuming. To overcome this, Johnson recruited Masters student Carlos Pulido to design a software pipeline called CRISPETa. They were assisted by a team of laboratory researchers including co-first authors of this paper Estel Aparicio and Carme Arnan, who carried out experiments to validate the software’s predictions.
CRISPETa is a powerful and flexible solution for designing CRISPR deletion experiments. The user tells CRISPETa what region they wish to delete, and the software returns a set of optimised pairs of sgRNAs that can directly be used by experimental researchers. One of the key features is that it can create designs at high scales, with future screening experiments in mind. Importantly, CRISPETa is designed for use by non-experts, and is available in a user friendly website, making CRISPR deletion available to the widest possible number of scientific and biomedical researchers.
In the CRISPETa study, the researchers also introduce a new version of DECKO, which is cheaper and faster than the previous one. The researchers showed that CRISPETa designs efficiently delete their desired targets in human cells. Most importantly, in those regions that give rise to RNA molecules, the researchers showed that the RNA molecules also carry the deletion.
CRISPETa will be useful for scientific researchers, from even the most modest experimental laboratory. These users may, for example, delete a suspected functional region of non-coding DNA, and test the outcome on cellular or molecular activity. This software will also be potentially valuable for groups aiming to utilise CRISPR deletion for therapeutic purposes, by for example, deleting a region of non-coding DNA that is suspected to cause a disease state. Therefore CRISPETa will be a valuable tool for the hundreds of research teams worldwide who are using CRISPR deletion.
«We hope that this new software tool will allow the greatest possible number of researchers to harness the power of CRISPR deletion in their research», says Carlos Pulido, the student who wrote the CRISPETa software.
«Ultimately, we expect that CRISPR deletion and other genome engineering tools to lead to a revolution in our ability to understand the genomic basis of disease, particularly in the 99% of DNA that does not encode proteins. Apart from being used as a basic research tool, CRISPR may even be used in the future as a powerful therapeutic to reverse disease-causing mutations», adds Rory Johnson.
Receive an email update when we add a new GENOMIC MEDICINE article.
The Latest on: Genomic medicine
via Google News
The Latest on: Genomic medicine
- Primary Children’s Hospital launches center with ‘cutting-edge’ genetic technologieson November 29, 2019 at 3:34 pm
Janell and Elliot Lewis and their daughter, Evie, attend the launch of the new Center for Personalized Medicine at Primary Children’s Hospital in Salt Lake City on Monday, Nov. 25, 2019. Evie was born ...
- Members of the public in the USA, UK, Canada and Australia expressing genetic exceptionalism say they are more willing to donate genomic dataon November 29, 2019 at 10:29 am
In other words, those interested in data donation appear aware of both what genetic information is and its value for research and genomic medicine. Risks associated with data sharing may be seen as ...
- Intermountain launches pediatric center for personalized medicineon November 26, 2019 at 9:41 pm
A new Center for Personalized Medicine, located at Intermountain Primary Children’s Hospital in Salt Lake City, will deliver targeted therapies to critically ill kids, based on their genetic makeup.
- 10x Genomics Begins Shipments of Visium Spatial Gene Expression Solutionon November 26, 2019 at 4:27 pm
Institutions like the New York Genome Center, Stanford University Genomics Facility and the University of Southern California (USC) Keck School of Medicine are among the first customers to receive the ...
- Genomics ETFs Surge on CRISPR's Gene Editing Progresson November 26, 2019 at 7:51 am
As a result, the characteristics of a cell or organism are changed. According to analysts, growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics ...
- How AI Is Helping Diagnose Rare Genetic Diseaseson November 25, 2019 at 9:14 am
This April, Fabric Genomics' algorithms were used by researchers at Rady Children's Institute for Genomic Medicine in San Diego, where machine-learning processes and clinical natural language ...
- The integration of genomics into clinical ophthalmic services in the UKon November 25, 2019 at 6:40 am
However, currently ophthalmic genomics is seen as a niche area practised by a small number of highly trained experts; but things are changing. As part of the NHS England Long Term plan there is now a ...
- Now 4 years old, Alabama genomic medicine clinic is changing liveson November 24, 2019 at 9:00 am
“I looked up a geneticist, and that’s how I found Dr. Bick,” Barnette said. “And he took him right in.” Dr. David Bick is a clinical geneticist at the Smith Family Clinic for Genomic Medicine at ...
- Aevi Genomic Medicine, Inc. Common Stock (GNMX) Earnings Report Dateon November 20, 2019 at 8:06 pm
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago ...
via Bing News